Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | HCK | P08631 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL116606 | 0.82 | ALDH1A1 (0.69) | ALDH1A1CYP3A4TDP1MAPK1CYP19A1 | |
| SCHEMBL5800828 | 0.82 | ALDH1A1 (0.59) | ALDH1A1CYP3A4TDP1MAPK1CYP19A1 | |
| SCHEMBL309832 | 0.82 | ALDH1A1 (0.59) | ALDH1A1CYP3A4MAPK1CYP19A1NQO2 | |
| SCHEMBL202288 | 0.82 | ALDH1A1 (0.69) | ALDH1A1CYP3A4MAPK1CYP19A1NQO2 | |
| SCHEMBL16752055 | 0.80 | MAPT (0.46) | ALDH1A1CYP3A4TDP1MAPK1SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL10988442 | 0.79 | ALDH1A1 (0.65) | ALDH1A1CYP3A4TDP1MAPK1CYP19A1 | |
| SCHEMBL2999328 | 0.79 | ALDH1A1 (0.65) | ALDH1A1CYP3A4MAPK1CYP19A1NQO2 | |
| SCHEMBL21611343 | 0.79 | ALDH1A1 (0.65) | ALDH1A1CYP3A4TDP1MAPK1CYP19A1 | |
| Hydrochloric Acid SCHEMBL3275940 | 0.79 | ALDH1A1 (0.65) | ALDH1A1CYP3A4TDP1MAPK1CYP19A1 | |
| SCHEMBL30365875 | 0.79 | ALDH1A1 (0.65) | ALDH1A1CYP3A4TDP1MAPK1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630563-B2 | Macrocyclic RIP2-kinase inhibitors | ONCODESIGN S.A. (FR) | 2026-05-19 | — | — | US | disclosed |
| CN-117623947-B | Synthesis method of bifenazate intermediate | 绍兴上虞新银邦生化有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260125396-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN S.A. (FR) | 2026-05-07 | — | — | US | disclosed |
| US-20260115199-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4720057-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260085073-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250304573-A1 | LYSERGIC ACID DERIVATIVES AND METHODS | UNIV FLORIDA STATE RES FOUND INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250263408-A1 | SPLEEN TYROSINE KINASE INHIBITORS | UNIQUEST PTY LTD (AU) | 2025-08-21 | — | — | US | disclosed |
| US-6262124-B1 | FOR ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS, FOR EXAMPLE, AS AGONISTS OF SPECIFIC NICOTINIC RECEPTOR SUBTYPES; FOR THERAPY OF DYSFUNCTION OF THE CENTRAL AND AUTONOMIC NERVOUS SYSTEMS | TARGACEPT, INC., A CORPORATION OF DELAWARE | 2001-07-17 | — | — | US | disclosed |
| WO-2001017943-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| US-6166048-A | Pharmaceutical compositions for inhibition of cytokine production and secretion | TARGACEPT, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000062767-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION | TARGACEPT, INC. (US) | 2000-10-26 | — | — | WO | disclosed |
| EP-1042274-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000023418-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-04-27 | — | — | WO | disclosed |
| US-5223623-A | 2-substituted-1(4)-aryl piperazines and the process for their preparation | SCHERING AG (DE) | 1993-06-29 | — | — | US | disclosed |
| EP-0491709-A1 | 2-SUBSTITUTED-1(4)-ARYL PIPERAZINES AND THE PROCESS FOR THEIR PREPARATION | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-07-01 | — | — | EP | disclosed |
| US-5051422-A | 2-substituted-1(4)-aryl piperazines and the process for their preparation | SCHERING AG (DE) | 1991-09-24 | — | — | US | disclosed |
| WO-1991004250-A1 | 2-SUBSTITUTED-1(4)-ARYL PIPERAZINES AND THE PROCESS FOR THEIR PREPARATION | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1991-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115199-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CCR6 | ALDH1A1 313/4885CYP3A4 742/4885TDP1 2556/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | ALDH1A1 3178/4885CYP3A4 4043/4885TDP1 1868/4885 |
| US-20250304573-A1 | LYSERGIC ACID DERIVATIVES AND METHODS | AADAT, HTR3A, HNMT | ALDH1A1 2036/4885CYP3A4 1815/4885TDP1 816/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | ALDH1A1 3094/4885CYP3A4 3719/4885TDP1 2304/4885 |
| US-20260125396-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | ALDH1A1 4830/4885CYP3A4 4314/4885TDP1 1696/4885 |
| US-20250263408-A1 | SPLEEN TYROSINE KINASE INHIBITORS | LCK, BTK, SYK | ALDH1A1 3003/4885CYP3A4 1071/4885TDP1 947/4885 |
| US-12630563-B2 | Macrocyclic RIP2-kinase inhibitors | RIPK1, RIPK2, RIPK3 | ALDH1A1 4757/4885CYP3A4 4618/4885TDP1 1086/4885 |
| US-20260085073-A1 | PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL3 | ALDH1A1 2586/4885CYP3A4 2504/4885TDP1 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.